Tekmira Pharmaceuticals is shifting focus after years of up-and-down development, planning to change its name and train its attention on hepatitis B.
Exelixis notched a crucial clinical success for its top oncology prospect, meeting its goals in a kidney cancer trial and clearing the way for a lucrative FDA nod.
Bristol-Myers Squibb flagged an early success for its Phase III Opdivo (nivolumab) study for kidney cancer, saying that an independent monitoring group concluded that its closely watched checkpoint inhibitor has beat Afinitor (everolimus) in improving overall survival for advanced patients.
Vermillion has tapped investors for money to fund the enhancement of its bioinformatics platform. The diagnostics and bioanalytics player pulled in a total of $18.8 million through a stock offering, a slice of which will be ploughed into biotech IT.
Illumina has introduced a suite of tools and software to help research organizations new to population-scale sequencing to get started with its HiSeq X Ten and Five systems. The move comes one month after BGI joined the large-scale sequencing field with a package that covers each step of the process, from sample preparation to data analysis.
Amgen's new immuno-oncology treatment demonstrated promising efficacy in a midstage trial on a rare blood cancer.
Aerie Pharmaceuticals, regaining momentum after a costly clinical setback, is planning to expand its R&D operation in North Carolina, pressing forward with a treatment for glaucoma.
Singapore, a nation working to raise its profile in the biopharma world, has kicked off the first-ever clinical trial of a locally invented drug, working with Duke University on a novel cancer treatment it hopes will spur more R&D.
Biogen and Eli Lilly, two drugmakers making big bets in Alzheimer's disease, are set to present clinical data on a pair of much-scrutinized projects with potential to change the industry's approach to the field.
Becton Dickinson has opened the doors of a new facility in Andover, MA, that's dedicated to R&D and manufacturing for novel products to better address the needs of Type 1 and Type 2 diabetes patients. The center is part of a renewed effort for BD in diabetes, after it has suffered difficulties due to pricing erosion.